Differential Inhibition of T Cell Receptor and STAT5 Signaling Pathways Determines the Immunomodulatory Effects of Dasatinib in Chronic Phase Chronic Myeloid Leukemia

Scientists studied the impact of dasatinib in chronic myeloid leukemia patients and compared with patients taking other tyrosine kinase inhibitors and healthy controls